Anixa Biosciences Inc (NASDAQ:ANIX) CEO Purchases $15,800.00 in Stock

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Anixa Biosciences Inc (NASDAQ:ANIX - Get Free Report) CEO Amit Kumar purchased 5,000 shares of Anixa Biosciences stock in a transaction dated Wednesday, July 30th. The stock was bought at an average price of $3.16 per share, with a total value of $15,800.00. Following the completion of the transaction, the chief executive officer owned 579,925 shares of the company's stock, valued at $1,832,563. This represents a 0.87% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Amit Kumar also recently made the following trade(s):

• On Friday, July 11th, Amit Kumar purchased 5,000 shares of Anixa Biosciences stock. The stock was bought at an average price of $3.15 per share, with a total value of $15,750.00.
• On Wednesday, June 4th, Amit Kumar bought 10,000 shares of Anixa Biosciences stock. The shares were acquired at an average price of $2.85 per share, with a total value of $28,500.00.

Anixa Biosciences Price Performance

ANIX stock traded up $0.08 during mid-day trading on Monday, hitting $3.09. 91,252 shares of the stock were exchanged, compared to its average volume of 108,293. The business has a fifty day moving average price of $3.20 and a 200 day moving average price of $2.96. Anixa Biosciences Inc has a 12 month low of $2.07 and a 12 month high of $4.20. The stock has a market capitalization of $99.60 million, a price-to-earnings ratio of -8.13 and a beta of 0.43.

Anixa Biosciences (NASDAQ:ANIX - Get Free Report) last issued its quarterly earnings results on Tuesday, June 3rd. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.01. As a group, equities analysts forecast that Anixa Biosciences Inc will post -0.41 EPS for the current fiscal year.

Institutional Investors Weigh In On Anixa Biosciences

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Renaissance Technologies LLC lifted its stake in shares of Anixa Biosciences by 36.5% in the 4th quarter. Renaissance Technologies LLC now owns 14,573 shares of the company's stock valued at $34,000 after acquiring an additional 3,900 shares during the last quarter. Millennium Management LLC bought a new stake in shares of Anixa Biosciences in the 4th quarter valued at about $26,000. LPL Financial LLC lifted its stake in shares of Anixa Biosciences by 37.2% in the 4th quarter. LPL Financial LLC now owns 42,937 shares of the company's stock valued at $100,000 after acquiring an additional 11,633 shares during the last quarter. Private Advisor Group LLC bought a new stake in shares of Anixa Biosciences in the 1st quarter valued at about $35,000. Finally, Jane Street Group LLC bought a new stake in shares of Anixa Biosciences in the 4th quarter valued at about $67,000. Institutional investors own 29.13% of the company's stock.

Analysts Set New Price Targets

ANIX has been the topic of several recent analyst reports. D. Boral Capital reaffirmed a "buy" rating and issued a $10.00 price target on shares of Anixa Biosciences in a report on Tuesday, June 10th. Wall Street Zen raised Anixa Biosciences from a "sell" rating to a "hold" rating in a report on Friday, June 6th. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Anixa Biosciences currently has a consensus rating of "Buy" and an average target price of $9.00.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.